What’s up With Enzolytics Inc (OTCMKTS: ENZC)?

Enzolytics Inc (OTCMKTS: ENZC) stock is up 2.24%, and it exited yesterday’s market for $0.28. Out of its 34.47M average share trading volume, there was 84K shares trading volume yesterday. The market capitalization of this stock is $783.89M, and the stock is continuing its upward movement. 

Moving up on account of advancing HIV treatment to trials 

The stock had surged yesterday after the company announced that it has definitive plans to take its  ITV-1 anti-HIV therapeutic ahead to the clinical trials, followed by distribution across Europe. At around 11:04 am, the shares had jumped 9% to $0.302. 

Initially, the ITV-1 anti-HIV therapeutic moved towards certification from the Bulgarian Drug Agency. However, the process was interrupted before it could have been finalized. But, the process brought out significant clinical trial results, which were also documented. 

ENZC becomes a potential investment stock for investors

This biotechnology company is now zooming in on the closing trial of the lead drug, which would become its major milestone for setting up anti-HIV therapy as a critical source of revenue. It has been observed that people interested in investments look for stocks that show the possibility of considerable gains and have sustained it over some time. Going by this standard, it would be worth it to look into ENZC stock. 

Over the past three weeks, this stock has jumped by almost 200%. This is the right time when investors must look closely at the company. 

Additionally, the company also announced in the recent past that it is looking into computer-based analysis use to accelerate discoveries related to healthcare. For that purpose, it has also collaborated with Intel Corporation.

All in all, ENZC is in a good position right now and the investors have a heads-up for this stock.